Physician
Emergeortho PA
Emergeortho PA was paid $20.97M by Medicaid between Jan 2018 and Dec 2024, across 96 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 28% of everything it billed.
33Billing provider infoEMERGEORTHO PA
DURHAM, NC 27704
DURHAM, NC 27704
33aNPI1376592964assigned 05/09/2006
33bProvider typeSports Medicine (Orthopaedic Surgery) Physician
28Total paid$20.97M
24GClaims671,140
24DCodes billed96
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Sports Medicine (Orthopaedic Surgery) Physician providers in North Carolina
Rank by total paid#1 of 20
Median peer was paid$19K
This provider vs. median1,083×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 67,576 | $1.85M | |
| 2019 | 78,582 | $2.15M | |
| 2020 | 57,179 | $1.62M | |
| 2021 | 98,642 | $2.97M | |
| 2022 | 106,937 | $3.52M | |
| 2023 | 119,051 | $3.92M | |
| 2024incomplete | 143,173 | $4.95M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 28% | 183,565 | 138,008 | $5.90M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 24% | 118,129 | 94,518 | $4.99M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 13% | 120,294 | 47,183 | $2.81M |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 11% | 43,884 | 28,719 | $2.35M |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 7.8% | 18,811 | 14,105 | $1.64M |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 2.1% | 22,846 | 8,897 | $438K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.7% | 8,620 | 6,820 | $359K |
| 97161 | 1.4% | 6,366 | 5,470 | $293K | |
| 64483 | 1.3% | 2,859 | 2,085 | $265K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 1.2% | 15,040 | 6,506 | $256K |
| 20610 | <1% | 9,293 | 7,138 | $200K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 13,538 | 5,189 | $191K |
84 more codes
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 1,719 | $157K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 1,355 | $129K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 4,783 | $108K |
| 73630 | <1% | 5,749 | $74K | |
| 73110 | <1% | 3,968 | $65K | |
| 95886 | <1% | 1,478 | $61K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 21,325 | $53K |
| 73562 | <1% | 2,899 | $47K | |
| 73610 | <1% | 2,958 | $46K | |
| 73130 | <1% | 3,315 | $46K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 1,358 | $42K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,021 | $40K |
| A4590 | Special casting material (e.g., fiberglass) | <1% | 2,713 | $37K |
| 27096 | <1% | 611 | $37K | |
| 95911 | <1% | 344 | $31K | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 18,574 | $30K |
| 72100 | <1% | 1,517 | $24K | |
| 72110 | <1% | 814 | $20K | |
| 80305 | <1% | 2,350 | $18K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 338 | $17K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 64 | $15K |
| 73140 | <1% | 933 | $14K | |
| 20611 | <1% | 384 | $12K | |
| 97016 | <1% | 1,572 | $10K | |
| L4361 | Walking boot, pneumatic and/or vacuum, with or without joints, with or without interface material, prefabricated, off-the-shelf | <1% | 71 | $10K |
| 76942 | <1% | 269 | $10K | |
| 73560 | <1% | 971 | $7K | |
| 73564 | <1% | 400 | $7K | |
| 62321 | <1% | 87 | $7K | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 1,427 | $7K |
| 99051 | <1% | 252 | $6K | |
| 62323 | <1% | 110 | $5K | |
| 76882 | <1% | 245 | $5K | |
| 73100 | <1% | 344 | $5K | |
| 64493 | <1% | 140 | $5K | |
| L3908 | Wrist hand orthosis, wrist extension control cock-up, non molded, prefabricated, off-the-shelf | <1% | 248 | $5K |
| 20550 | <1% | 438 | $5K | |
| 99243 | <1% | 44 | $4K | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 2,163 | $4K |
| 95909 | <1% | 73 | $4K | |
| 29075 | <1% | 71 | $3K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 13 | $3K |
| L4387 | Walking boot, non-pneumatic, with or without joints, with or without interface material, prefabricated, off-the-shelf | <1% | 42 | $3K |
| 77002 | <1% | 123 | $3K | |
| 99442 | <1% | 89 | $3K | |
| 73030 | <1% | 267 | $3K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 16 | $2K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,385 | $2K |
| 64494 | <1% | 137 | $2K | |
| 97165 | <1% | 46 | $2K | |
| 20552 | <1% | 130 | $2K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 258 | $2K |
| 97010 | <1% | 1,038 | $2K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 184 | $1K |
| L3809 | Wrist hand finger orthosis, without joint(s), prefabricated, off-the-shelf, any type | <1% | 13 | $1K |
| 73600 | <1% | 144 | $1K | |
| 96160 | <1% | 908 | $1K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 176 | $1K |
| 64495 | <1% | 60 | $1K | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 303 | $934.54 |
| J0897 | Injection, denosumab, 1 mg | <1% | 16 | $826.20 |
| 72040 | <1% | 38 | $824.38 | |
| 99443 | <1% | 34 | $805.15 | |
| J3490 | Unclassified drugs | <1% | 7,390 | $613.84 |
| 29105 | <1% | 12 | $605.84 | |
| 72170 | <1% | 118 | $604.31 | |
| 72082 | <1% | 14 | $559.49 | |
| 73502 | <1% | 88 | $550.32 | |
| 97035 | <1% | 111 | $482.31 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 230 | $450.74 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 350 | $372.36 |
| 11721 | <1% | 93 | $278.33 | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 124 | $267.51 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 36 | $262.27 |
| 99406 | <1% | 47 | $259.49 | |
| 73565 | <1% | 36 | $197.86 | |
| 73501 | <1% | 24 | $183.06 | |
| 97022 | <1% | 41 | $137.58 | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 113 | $66.58 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 91 | $61.38 |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 13 | $57.22 |
| 36415 | Collection of venous blood by venipuncture | <1% | 14 | $27.00 |
| 82962 | <1% | 22 | $11.80 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHARVEY, DARCI (DIRECTOR OF VBO)